Breakthrough business models: drug development for rare and neglected diseases and individualized therapies: workshop summary
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
National Academies Press
c2009
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Includes bibliographical references Introduction and overview -- Current model for financing drug development: from concept through approval -- The Food and Drug Administration's Orphan Drug Program -- Diverse funding models -- Strategies for facilitating sharing of research materials and data -- Strategies of navigation intellectual property -- Strategies for facilitating clinical trials -- Summary "The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to explore innovative strategies for orphan drug development." |
| Beschreibung: | 1 Online-Ressource (xviii, 132 p.) |
| ISBN: | 0309120888 0309120896 9780309120883 9780309120890 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043114791 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2009 |||| o||u| ||||||eng d | ||
| 020 | |a 0309120888 |9 0-309-12088-8 | ||
| 020 | |a 0309120896 |c electronic bk. |9 0-309-12089-6 | ||
| 020 | |a 9780309120883 |9 978-0-309-12088-3 | ||
| 020 | |a 9780309120890 |c electronic bk. |9 978-0-309-12089-0 | ||
| 035 | |a (OCoLC)311565225 | ||
| 035 | |a (DE-599)BVBBV043114791 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 362.17/820973 |2 22 | |
| 245 | 1 | 0 | |a Breakthrough business models |b drug development for rare and neglected diseases and individualized therapies: workshop summary |c [edited by] Theresa Wizeman, Sally Robinson, and Robert Giffin ; Forum on Drug Discovery, Development, and Translation, Board on Health Services Policy, Institute of Medicine of the National Academies |
| 246 | 1 | 3 | |a Drug development for rare and neglected diseases and individualized therapies |
| 264 | 1 | |a Washington, D.C. |b National Academies Press |c c2009 | |
| 300 | |a 1 Online-Ressource (xviii, 132 p.) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references | ||
| 500 | |a Introduction and overview -- Current model for financing drug development: from concept through approval -- The Food and Drug Administration's Orphan Drug Program -- Diverse funding models -- Strategies for facilitating sharing of research materials and data -- Strategies of navigation intellectual property -- Strategies for facilitating clinical trials -- Summary | ||
| 500 | |a "The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to explore innovative strategies for orphan drug development." | ||
| 650 | 7 | |a MEDICAL / Allied Health Services / General |2 bisacsh | |
| 650 | 7 | |a Drugs / Design |2 fast | |
| 650 | 7 | |a Orphan drugs / Government policy |2 fast | |
| 650 | 7 | |a Pharmaceutical policy |2 fast | |
| 650 | 4 | |a Orphan Drug Production / economics / United States | |
| 650 | 4 | |a Orphan Drug Production / trends / United States | |
| 650 | 4 | |a Models, Economic / United States | |
| 650 | 4 | |a Research / economics / United States | |
| 650 | 4 | |a Research / trends / United States | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Politik | |
| 650 | 4 | |a Orphan drugs |x Government policy |z United States | |
| 650 | 4 | |a Pharmaceutical policy |z United States | |
| 650 | 4 | |a Drugs |z United States |x Design | |
| 651 | 4 | |a USA | |
| 700 | 1 | |a Wizemann, Theresa M. |e Sonstige |4 oth | |
| 700 | 1 | |a Robinson, Sally |e Sonstige |4 oth | |
| 700 | 1 | |a Giffin, Robert B. |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.) |b Forum on Drug Discovery, Development, and Translation |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=272064 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028538982 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=272064 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=272064 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175538315591680 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043114791 |
| collection | ZDB-4-EBA |
| ctrlnum | (OCoLC)311565225 (DE-599)BVBBV043114791 |
| dewey-full | 362.17/820973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 362 - Social problems and services to groups |
| dewey-raw | 362.17/820973 |
| dewey-search | 362.17/820973 |
| dewey-sort | 3362.17 6820973 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Soziologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03523nmm a2200613zc 4500</leader><controlfield tag="001">BV043114791</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2009 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309120888</subfield><subfield code="9">0-309-12088-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309120896</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-309-12089-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309120883</subfield><subfield code="9">978-0-309-12088-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309120890</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-309-12089-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)311565225</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043114791</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.17/820973</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Breakthrough business models</subfield><subfield code="b">drug development for rare and neglected diseases and individualized therapies: workshop summary</subfield><subfield code="c">[edited by] Theresa Wizeman, Sally Robinson, and Robert Giffin ; Forum on Drug Discovery, Development, and Translation, Board on Health Services Policy, Institute of Medicine of the National Academies</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Drug development for rare and neglected diseases and individualized therapies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">c2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xviii, 132 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Introduction and overview -- Current model for financing drug development: from concept through approval -- The Food and Drug Administration's Orphan Drug Program -- Diverse funding models -- Strategies for facilitating sharing of research materials and data -- Strategies of navigation intellectual property -- Strategies for facilitating clinical trials -- Summary</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to explore innovative strategies for orphan drug development."</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Allied Health Services / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Design</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Orphan drugs / Government policy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical policy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Orphan Drug Production / economics / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Orphan Drug Production / trends / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Models, Economic / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Research / economics / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Research / trends / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Politik</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Orphan drugs</subfield><subfield code="x">Government policy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical policy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="z">United States</subfield><subfield code="x">Design</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wizemann, Theresa M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robinson, Sally</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giffin, Robert B.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Forum on Drug Discovery, Development, and Translation</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=272064</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028538982</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=272064</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=272064</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043114791 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:17:53Z |
| institution | BVB |
| isbn | 0309120888 0309120896 9780309120883 9780309120890 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028538982 |
| oclc_num | 311565225 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 Online-Ressource (xviii, 132 p.) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | Breakthrough business models drug development for rare and neglected diseases and individualized therapies: workshop summary [edited by] Theresa Wizeman, Sally Robinson, and Robert Giffin ; Forum on Drug Discovery, Development, and Translation, Board on Health Services Policy, Institute of Medicine of the National Academies Drug development for rare and neglected diseases and individualized therapies Washington, D.C. National Academies Press c2009 1 Online-Ressource (xviii, 132 p.) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references Introduction and overview -- Current model for financing drug development: from concept through approval -- The Food and Drug Administration's Orphan Drug Program -- Diverse funding models -- Strategies for facilitating sharing of research materials and data -- Strategies of navigation intellectual property -- Strategies for facilitating clinical trials -- Summary "The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to explore innovative strategies for orphan drug development." MEDICAL / Allied Health Services / General bisacsh Drugs / Design fast Orphan drugs / Government policy fast Pharmaceutical policy fast Orphan Drug Production / economics / United States Orphan Drug Production / trends / United States Models, Economic / United States Research / economics / United States Research / trends / United States Medizin Politik Orphan drugs Government policy United States Pharmaceutical policy United States Drugs United States Design USA Wizemann, Theresa M. Sonstige oth Robinson, Sally Sonstige oth Giffin, Robert B. Sonstige oth Institute of Medicine (U.S.) Forum on Drug Discovery, Development, and Translation Sonstige oth http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=272064 Aggregator Volltext |
| spellingShingle | Breakthrough business models drug development for rare and neglected diseases and individualized therapies: workshop summary MEDICAL / Allied Health Services / General bisacsh Drugs / Design fast Orphan drugs / Government policy fast Pharmaceutical policy fast Orphan Drug Production / economics / United States Orphan Drug Production / trends / United States Models, Economic / United States Research / economics / United States Research / trends / United States Medizin Politik Orphan drugs Government policy United States Pharmaceutical policy United States Drugs United States Design |
| title | Breakthrough business models drug development for rare and neglected diseases and individualized therapies: workshop summary |
| title_alt | Drug development for rare and neglected diseases and individualized therapies |
| title_auth | Breakthrough business models drug development for rare and neglected diseases and individualized therapies: workshop summary |
| title_exact_search | Breakthrough business models drug development for rare and neglected diseases and individualized therapies: workshop summary |
| title_full | Breakthrough business models drug development for rare and neglected diseases and individualized therapies: workshop summary [edited by] Theresa Wizeman, Sally Robinson, and Robert Giffin ; Forum on Drug Discovery, Development, and Translation, Board on Health Services Policy, Institute of Medicine of the National Academies |
| title_fullStr | Breakthrough business models drug development for rare and neglected diseases and individualized therapies: workshop summary [edited by] Theresa Wizeman, Sally Robinson, and Robert Giffin ; Forum on Drug Discovery, Development, and Translation, Board on Health Services Policy, Institute of Medicine of the National Academies |
| title_full_unstemmed | Breakthrough business models drug development for rare and neglected diseases and individualized therapies: workshop summary [edited by] Theresa Wizeman, Sally Robinson, and Robert Giffin ; Forum on Drug Discovery, Development, and Translation, Board on Health Services Policy, Institute of Medicine of the National Academies |
| title_short | Breakthrough business models |
| title_sort | breakthrough business models drug development for rare and neglected diseases and individualized therapies workshop summary |
| title_sub | drug development for rare and neglected diseases and individualized therapies: workshop summary |
| topic | MEDICAL / Allied Health Services / General bisacsh Drugs / Design fast Orphan drugs / Government policy fast Pharmaceutical policy fast Orphan Drug Production / economics / United States Orphan Drug Production / trends / United States Models, Economic / United States Research / economics / United States Research / trends / United States Medizin Politik Orphan drugs Government policy United States Pharmaceutical policy United States Drugs United States Design |
| topic_facet | MEDICAL / Allied Health Services / General Drugs / Design Orphan drugs / Government policy Pharmaceutical policy Orphan Drug Production / economics / United States Orphan Drug Production / trends / United States Models, Economic / United States Research / economics / United States Research / trends / United States Medizin Politik Orphan drugs Government policy United States Pharmaceutical policy United States Drugs United States Design USA |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=272064 |
| work_keys_str_mv | AT wizemanntheresam breakthroughbusinessmodelsdrugdevelopmentforrareandneglecteddiseasesandindividualizedtherapiesworkshopsummary AT robinsonsally breakthroughbusinessmodelsdrugdevelopmentforrareandneglecteddiseasesandindividualizedtherapiesworkshopsummary AT giffinrobertb breakthroughbusinessmodelsdrugdevelopmentforrareandneglecteddiseasesandindividualizedtherapiesworkshopsummary AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation breakthroughbusinessmodelsdrugdevelopmentforrareandneglecteddiseasesandindividualizedtherapiesworkshopsummary AT wizemanntheresam drugdevelopmentforrareandneglecteddiseasesandindividualizedtherapies AT robinsonsally drugdevelopmentforrareandneglecteddiseasesandindividualizedtherapies AT giffinrobertb drugdevelopmentforrareandneglecteddiseasesandindividualizedtherapies AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation drugdevelopmentforrareandneglecteddiseasesandindividualizedtherapies |